[1] |
中国医师协会皮肤科医师分会自身免疫性疾病亚专业委员会. 寻常型天疱疮诊断和治疗的专家建议[J]. 中华皮肤科杂志, 2016,49(11):761⁃765. doi: 10.3760/cma.j.issn.0412⁃4030. 2016.11.01
|
[2] |
Huang YH, Kuo CF, Chen YH, et al. Incidence, mortality, and causes of death of patients with pemphigus in Taiwan: a nationwide population⁃based study[J]. J Invest Dermatol, 2012,132(1):92⁃97. doi: 10.1038/jid.2011.249.
|
[3] |
Wang YL, Tie D, Yan TM, et al. Survey of the epidemiology of autoimmune bullous disorders in Peking Union Medical College Hospital: a 30⁃year review[J]. Eur J Dermatol, 2017,27(3):331⁃332. doi: 10.1684/ejd.2017.3010.
|
[4] |
Harman KE, Brown D, Exton LS, et al. British Association of Dermatologists′ guidelines for the management of pemphigus vulgaris 2017[J]. Br J Dermatol, 2017,177(5):1170⁃1201. doi: 10.1111/bjd.15930.
|
[5] |
Amagai M, Tanikawa A, Shimizu T, et al. Japanese guidelines for the management of pemphigus[J]. J Dermatol, 2014,41(6):471⁃486. doi: 10.1111/1346⁃8138.12486.
|
[6] |
Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus[J]. J Am Acad Dermatol, 2008,58(6):1043⁃1046. doi: 10.1016/j.jaad.2008.01.012.
|
[7] |
陈喜雪, 朱学骏. 天疱疮及大疱性类天疱疮的治疗[J]. 继续医学教育, 2006,20(23):54⁃56. doi: 10.3969/j.issn.1004⁃6763. 2006.23.015.
|
[8] |
Shimizu T, Takebayashi T, Sato Y, et al. Grading criteria for disease severity by pemphigus disease area index[J]. J Dermatol, 2014,41(11):969⁃973. doi: 10.1111/1346⁃8138.12649.
|
[9] |
Murrell DF, Peña S, Joly P, et al. Diagnosis and management of pemphigus: recommendations by an international panel of experts[J]. J Am Acad Dermatol, 2018. pii: S0190⁃9622(18)30207⁃X. doi: 10.1016/j.jaad.2018.02.021.
|
[10] |
Hertl M, Jedlickova H, Karpati S, et al. Pemphigus. S2 Guideline for diagnosis and treatment⁃⁃guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV)[J]. J Eur Acad Dermatol Venereol, 2015,29(3):405⁃414. doi: 10.1111/jdv. 12772.
|
[11] |
Stanley JR. Therapy of pemphigus vulgaris[J]. Arch Dermatol. 1999,135(1):76⁃8.
|
[12] |
Mimouni D, Bar H, Gdalevich M, et al. Pemphigus⁃⁃analysis of epidemiological factors in 155 patients[J]. J Eur Acad Dermatol Venereol, 2008,22(10):1232⁃1235. doi: 10.1111/j.1468⁃3083. 2008.02786.x.
|
[13] |
Almugairen N, Hospital V, Bedane C, et al. Assessment of the rate of long⁃term complete remission off therapy in patients with pemphigus treated with different regimens including medium⁃ and high⁃dose corticosteroids[J]. J Am Acad Dermatol, 2013,69(4):583⁃588. doi: 10.1016/j.jaad.2013.05.016.
|
[14] |
Wang M, Gao Y, Peng Y, et al. Yearly reduction of glucocorticoid dose by 50% as tapering schedule achieves complete remission for 124 pemphigus vulgaris patients[J]. J Dermatol, 2016,43(3):325⁃328. doi: 10.1111/1346⁃8138.13071.
|
[15] |
Ioannides D, Apalla Z, Lazaridou E, et al. Evaluation of mycophenolate mofetil as a steroid⁃sparing agent in pemphigus: a randomized, prospective study[J]. J Eur Acad Dermatol Venereol, 2012,26(7):855⁃860. doi: 10.1111/j.1468⁃3083.2011. 04170.x.
|
[16] |
Eming R, Sticherling M, Hofmann SC, et al. S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid[J]. J Dtsch Dermatol Ges, 2015,13(8):833⁃844. doi: 10.1111/ddg.12606.
|
[17] |
Yan W, Zhou YH, Wang L, et al. NUDT15 polymorphism and severe azathioprine⁃induced myelosuppression in a Chinese man with pemphigus vulgaris[J]. Br J Dermatol, 2018,178(1):e40⁃e41. doi: 10.1111/bjd.15840.
|
[18] |
Joly P, Maho⁃Vaillant M, Prost⁃Squarcioni C, et al. First⁃line rituximab combined with short⁃term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel⁃group, open⁃label randomised trial[J]. Lancet, 2017,389(10083):2031⁃2040. doi: 10.1016/S0140⁃6736(17)30070⁃3.
|
[19] |
Tavakolpour S. Current and future treatment options for pemphigus: Is it time to move towards more effective treatments?[J]. Int Immunopharmacol, 2017,53:133⁃142. doi: 10.1016/j.intimp.2017.10.027.
|
[20] |
Kolesnik M, Becker E, Reinhold D, et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication[J]. J Eur Acad Dermatol Venereol, 2014,28(6):771⁃780. doi: 10.1111/jdv.12175.
|
[21] |
Wang M, Cao C, Sun J, et al. Application of autologous hematopoietic stem cell transplantation for pemphigus[J]. Int J Dermatol, 2017,56(3):296⁃301. doi: 10.1111/ijd.13461.
|
[22] |
Suslova IM, Theodoropoulos DS, Cullen NA, et al. Pemphigus vulgaris treated with allogeneic hematopoietic stem cell transplantation following non⁃myeloablative conditioning[J]. Eur Rev Med Pharmacol Sci, 2010,14(9):785⁃788.
|
[23] |
Vanikar AV, Modi PR, Patel RD, et al. Hematopoietic stem cell transplantation in autoimmune diseases: the Ahmedabad experience[J]. Transplant Proc, 2007,39(3):703⁃708. doi: 10. 1016/j.transproceed.2007.01.070.
|